Skip to main content

Advertisement

SpringerLink
Log in

Prevention of Complications and Symptomatic Recurrences in Diverticular Disease with Mesalazine: A 12-Month Follow-up

  • Original Paper
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

In uncomplicated diverticular disease, treatment is aimed at relieving symptoms. The aim of the present study was to evaluate the efficacy of mesalazine for symptomatic relief of uncomplicated diverticular disease of the colon. Two hundred sixty-eight consecutive eligible outpatients (122 male, 146 female; age, 66.1 years; range, 31–81 years) were enrolled in four treatment schedules in a randomized fashion: Group R1 (66 patients), rifaximin, 200 mg bid; Group R2 (69 patients), rifaximin, 400 mg bid; Group M1 (67 patients), mesalazine, 400 mg bid; and Group M2 (66 patients), mesalazine, 800 mg bid. Treatments were administered for 10 days every month for 12 months. Clinical evaluations were performed at admission and at 3-month intervals for 12 months considering 12 clinical variables (upper and lower abdominal pain/discomfort, tenesmus, diarrhea, abdominal tenderness, fever, bloating, general illness, nausea, emesis, dysuria, bleeding) graded as 0 = no symptoms, 1 = mild, 2 = moderate, and 3 = severe. The Global Symptomatic Score (GSS) was calculated using the sum of each symptom score. Two hundred forty-four patients completed the 12- month study; 24 were discontinued (14 treated with rifaximin and 10 treated with mesalazine) either as voluntary dropouts or because they developed side effects and/or complications. Group M2 demonstrated a lower frequency of many symptoms after 6 and 12 months of treatment; the mean GSS was significantly lower in Group M2 after 6 and 12 months of therapy by both intention-to-treat and per-protocol analyses. Patients treated with mesalazine (Groups M1+M2) had a lower GSS than subjects treated with rifaximin (Groups R1+R2) during the 12-month follow-up period. We conclude that cyclic administration of mesalazine is effective for symptomatic relief of uncomplicated diverticular disease of the colon. Some symptoms showed greater improvement with mesalazine, 800 mg bid, than with the other treatment schedules.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Stollman NH, Baskin JB, for and on behalf of the Ad Hoc Practice Parameters Committee of the American College of Gastroenterology (1999) Diagnosis and management of diverticular disease of the colon in adults. Practice guidelines. Am J Gastroenterol 94(11):3110–3121

    Article  PubMed  CAS  Google Scholar 

  2. Salzman H, Dustin L (2005) Diverticular disease: diagnosis and treatment. Am Fam Phys 72(7):1230–1234

    Google Scholar 

  3. Almy TP, Howell DA (1980) Diverticular disease of the colon. N Engl J Med 302:324–331

    Article  PubMed  CAS  Google Scholar 

  4. Kohler L, Sauerland S, Neugebauer E, for the Scientific Committee of the European Association for Endoscopic Surgery (1999) Diagnosis and treatment of diverticular disease. Results of a consensus development conference. Surg Endosc 13:430–436

    Article  PubMed  CAS  Google Scholar 

  5. Schwartz JT, Graham DY (1998) Diverticular disease of the large intestine. In: Diseases of the colon, rectum and anal canal. Kirsner J, Shorter R (eds). Williams & Wilkins, Baltimore, pp 519–536

    Google Scholar 

  6. Naitove A, Smith RE (1993) Diverticular disease of the colon. In: Gastrointestinal disease, 5th ed. Sleisenger MH, Fordtran TS (eds). Saunders, Philadelphia, pp 1347–1363

    Google Scholar 

  7. Aldoori WH, Giovannucci EL, Rockett HR, et al. (1998) A prospective study of dietary fiber types and symptomatic diverticular disease in men. J Nutr 128:714–719

    PubMed  CAS  Google Scholar 

  8. Brodribb AJ (1977) Treatment of symptomatic diverticular disease with a high-fibre diet. Lancet 1(8013):664–666

    Article  PubMed  CAS  Google Scholar 

  9. Ewerth S, Ahlberg J, Holmstrom B, Persson U, Uden R (1980) Influence on symptoms and transit time of Vi SiblinR in diverticular disease. Acta Chir Scand 500:40–59

    Google Scholar 

  10. Solotoft J, Gudmand-Hoyer E, Krag B, Kristensen E, Wulff HR (1976) A double blind trial of wheat bran on symptoms of irritable bowel syndrome. Lancet 1(7954):270–272

    Article  Google Scholar 

  11. Fric P, Zavoral M (2003) The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur J Gastroenterol Hepatol 15(3):313–315

    Article  PubMed  Google Scholar 

  12. Papi C, Ciaco A, Koch M, et al. (1995) Efficacy of rifaximine in the treatmentof symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. Aliment Pharmacol Ther 9:33–39

    Article  PubMed  CAS  Google Scholar 

  13. Latella G, Pimpo MT, Sottili S, et al. (2003) Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis 18:55–62

    Article  PubMed  Google Scholar 

  14. Stollman N, Raskin JB (2004) Diverticular disease of the colon. Lancet 363:631–639

    Article  PubMed  Google Scholar 

  15. Bassotti G, Chistolini F, Morelli A (2003) Pathophysiological aspects of diverticular disease of colon and role of large bowel motilità. World J Gastroenterol 9(10):2140–2142

    PubMed  Google Scholar 

  16. Simpson J, Scholefield JH, Spiller RC (2002) Pathogenesis of colonic diverticula. Br J Surgery 89:546–554

    Article  CAS  Google Scholar 

  17. Bode MK, Karttunen TJ, Makela J, et al. (2000) Type I and III collagens in human colon cancer and diverticulosis. Scand J Gastroenterol 35:747–752

    Article  PubMed  CAS  Google Scholar 

  18. Painter NS, Burkitt DP (1975) Diverticular disease of the colon, a 20th century problem. Clin Gastroenterol 4:3–21

    PubMed  CAS  Google Scholar 

  19. Ghorai S, Ulbright TM, Douglas K, et al. (2003) Endoscopic findings of diverticular inflammation in colonscopy patients with clinical acute diverticulitis: prevalence and endoscopic spectrum. Am J Gastroenterol 98(4):76–84

    Article  Google Scholar 

  20. Makapugay LM, Dean PJ (1996) Diverticular disease-associated chronic colitis. Am J Surg Pathol 20(1):94–102

    Article  PubMed  CAS  Google Scholar 

  21. Peppercorn MA (2004) The overlap of inflammatory bowel disease and diverticular disease. J Clin Gastroenterol 38 (Suppl 1):S8–S10

    Article  PubMed  Google Scholar 

  22. Sheperd NA (1996) Diverticular disease and chronic idiopathic inflammatory bowel disease: associations and masquerades. Gut 38:801–802

    Article  Google Scholar 

  23. Tursi A (2005) Mesalazine for diverticular disease of the colon-a new role for an old drug. Expert Opin Pharmacother 6(1):69–74

    Article  PubMed  CAS  Google Scholar 

  24. Eliakim R, Rachmilewitz D (1992) Potenzial mediators in inflammatory bowel disease. Gastroenterol Int 5:48–56

    Google Scholar 

  25. Grisham MB (1994) Oxidants and free radicals in inflammatory bowel disease. Lancet 344:859–861

    Article  PubMed  CAS  Google Scholar 

  26. Wood AJJ (1996) Inflammatory bowel disease. N Engl J Med 334:841–848

    Article  Google Scholar 

  27. Goncalves E, Almeida LM, Dinis TC (1998) Antioxidant activity of 5-aminosalicylic acid against peroxidation of phosphatidylcholine liposomes in the presence of alpha-tocopherol: A synergistic interaction? Free Rad Res 29:53–66

    Article  CAS  Google Scholar 

  28. Gore S, Sheperd NA, Wilkinson SP (1992) Endoscopic crescentic fold disease of the sigmoid colon: the clinical and hystopathological spectrum of a distinctive endoscopic appearance. Int J Colorect Dis 7:76–81

    Article  CAS  Google Scholar 

  29. Tursi A (2004) Diverticular disease of the colon. Lancet 363:1397–1398

    Article  PubMed  Google Scholar 

  30. Peppercorn MA (1992) Drug-responsive chronic segmental colitis associated with diverticula: a clinical syndrome in the elderly. Am J Gastroenterol 87:609–612

    PubMed  CAS  Google Scholar 

  31. Trespi E, Colla C, Panizza P, Polino MG, Venturini A, Bottani G, De Vecchi P, Matti C (1999) Ruolo terapeutico e profilattico della mesalazina (5-ASA) nella malattia diverticolare sintomatica del crasso. Minerva Gastroenterol Dietol 45:245–252

    Google Scholar 

  32. Tursi A, Brandimarte G, Daffinà R (2002) Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon. Dig Liver Dis 34:510–515

    Article  PubMed  CAS  Google Scholar 

  33. Di Mario F, Aragona G, Leandro G, et al. (2005) Efficacy of mesalazine in the treatment of symptomatic diverticular disease. Dig Dis Sci 50:581–586

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

This work was conducted under the auspices of the Roberto Farini Foundation for Gastroenterological Research.

Author information

Authors and Affiliations

  1. Department of Clinical Sciences, Chair of Gastroenterology, University of Parma, Parma, Italy

    Giuseppe Comparato, Libera Fanigliulo, Lucas G Cavallaro, Giulia Martina Cavestro, Veronica Iori, Marta Maino & Francesco Di. Mario

  2. Gastroenterology and Endoscopy Unit, Az. Ospedaliera, Piacenza, Italy

    Giovanni Aragona

  3. U.O. Chirurgia Borgovalditaro, AUSL, Parma, Italy

    Giancarlo Mazzocchi

  4. Gastroenterology and Endoscopy Unit, Az. Ospedaliera, Parma, Italy

    Pierantonio Muzzetto, Giancarlo Colla & Angelo Franzé

  5. Department of General Surgery and Organ Transplantation, University of Parma, Parma, Italy

    Mario Sianesi

  6. Università degli Studi di Parma, Dipartimento di Scienze Cliniche, Sezione di Gastroenterologia, Via Gramsci 14, 43100, Parma, Italy

    Francesco Di. Mario

Authors
  1. Giuseppe Comparato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Libera Fanigliulo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lucas G Cavallaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Giovanni Aragona
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giulia Martina Cavestro
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Veronica Iori
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Marta Maino
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Giancarlo Mazzocchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Pierantonio Muzzetto
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Giancarlo Colla
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Mario Sianesi
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Angelo Franzé
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Francesco Di. Mario
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesco Di. Mario.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Comparato, G., Fanigliulo, L., Cavallaro, L.G. et al. Prevention of Complications and Symptomatic Recurrences in Diverticular Disease with Mesalazine: A 12-Month Follow-up. Dig Dis Sci 52, 2934–2941 (2007). https://doi.org/10.1007/s10620-007-9766-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-007-9766-8

Keywords

Search

Navigation